See the original post:
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
Related Post
- Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - January 7th, 2025
- Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - January 7th, 2025
- Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - January 7th, 2025
- ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Kura Oncology Announces Senior Executive Promotions - January 7th, 2025
- Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Umoja Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - January 7th, 2025
- Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - January 7th, 2025
- Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering - January 7th, 2025
- Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide - January 7th, 2025
- Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope - January 7th, 2025
- Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe - January 7th, 2025
- Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study - January 7th, 2025
- Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights - January 7th, 2025
- Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development - January 3rd, 2025
- Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics - January 3rd, 2025
- TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses - January 3rd, 2025
- Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - January 3rd, 2025
- Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Lexicon Appoints Scott Coiante as Chief Financial Officer - January 3rd, 2025
- Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - January 3rd, 2025
- SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET - January 3rd, 2025
- Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - January 3rd, 2025
- Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular... - January 3rd, 2025
- Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference - January 3rd, 2025
- Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update - January 3rd, 2025
- Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 3rd, 2025
- ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 3rd, 2025
- Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering - January 1st, 2025
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals - January 1st, 2025
- Burning Rock Announces Results of 2024 Annual General Meeting - January 1st, 2025
- Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants - January 1st, 2025
- Oncotelic Therapeutics Implements PDAOAI Platform - January 1st, 2025
- Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - January 1st, 2025
- Firefly Neuroscience Closes on Financing of up to $12.4 Million - January 1st, 2025
- Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA - January 1st, 2025
- SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder - January 1st, 2025
- HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture - January 1st, 2025
- European Commission approves RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with... - December 30th, 2024
- Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA - December 30th, 2024
- Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging - December 30th, 2024
- Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies - December 30th, 2024
- Orion and Marinus terminate agreement for ganaxolone in Europe - December 30th, 2024
- Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson - December 30th, 2024
- Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - December 30th, 2024
- Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia - December 30th, 2024
- Hit Refresh in the New Year with Tilray's Premium Non-Alcohol Beverage Lineup - December 30th, 2024
- Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth - December 30th, 2024
- New Year, New Chill: Explore the Latest Cannabis Beverages from Solei, Mollo, and XMG - December 30th, 2024
- Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand - December 30th, 2024
- Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of... - December 30th, 2024
- Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV - December 30th, 2024
- NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports - December 30th, 2024
- 2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025 - December 30th, 2024
- ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 30th, 2024
- Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million - December 30th, 2024
- argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating... - December 28th, 2024
- Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering - December 28th, 2024
- Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - December 28th, 2024
- Vor Bio Announces $55.6 Million Private Placement - December 28th, 2024
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - December 28th, 2024
- Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - December 28th, 2024
- Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements - December 27th, 2024
- COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - December 27th, 2024
- Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs - December 27th, 2024
- Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia - December 27th, 2024
- Spectral AI Announces Confirmation of Compliance of its Nasdaq Listing Requirements - December 27th, 2024
- Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
Recent Comments